INSYS THERAPEUTICS, INC. INDEMNITY AGREEMENTIndemnity Agreement • March 30th, 2011 • Insys Therapeutics, Inc. • Arizona
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between INSYS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
INSYS THERAPEUTICS, INC. Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 16th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
INSYS THERAPEUTICS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • April 25th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Arizona
This Amended and Restated Employment Agreement (“Agreement”) is entered into as of the 18th day of April, 2013 (the “Effective Date”), by and between Michael L. Babich (“Executive”) and Insys Therapeutics, Inc. (the “Company”).
ASSET PURCHASE AGREEMENT BETWEEN PHARMBIO KOREA, INC. AND INSYS THERAPEUTICS, INC. DATED AS OF SEPTEMBER 25, 2019Asset Purchase Agreement • September 26th, 2019 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
other Assigned Patents. All questions concerning the construction, validity and interpretation of this Assignment and the performance of the obligations imposed by this Assignment shall be governed by, and construed in accordance with, the Laws of the State of New York (without regard to the choice of Law principles thereof) and the intellectual property Laws of the United States without giving effect to any Law that would result in the application of a different body of Law than as set forth in this Section 3, except to the extent that such Laws are superseded by the Bankruptcy Code.
INSYS THERAPEUTICS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • April 19th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Arizona
This Amended and Restated Employment Agreement (“Agreement”) is entered into as of the 18th day of April, 2013 (the “Effective Date”), by and between Dr. Larry Dillaha (“Executive”) and Insys Therapeutics, Inc. (the “Company”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 11th, 2018 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Arizona
This Employment Agreement (this “Agreement”) is made and entered into as of October 10, 2018, (the “Effective Date”), by and among Insys Therapeutics, Inc. (the “Company”) and Mark E. Nance (“Executive”) (the Company and Executive, collectively, the “Parties”).
MANUFACTURING AGREEMENT DPT LAKEWOOD, LLC AND INSYS THERAPEUTICSManufacturing Agreement • February 27th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
This Manufacturing Agreement (the “Agreement”) is made as of this 24th day of May, 2011 (the “Effective Date”) by and between Insys Therapeutics, a corporation organized under the laws of the State of Delaware with its principal place of business at 10220 South 51st Street, Suite 2, Phoenix, AZ 85044 (hereinafter referred to as “COMPANY”) and DPT Lakewood, LLC, a corporation organized under the laws of the State of Delaware with a place of business at 1200 Paco Way, Lakewood, New Jersey, 08701, including its affiliate DPT Laboratories, Ltd. (hereinafter collectively referred to as “DPT”).
VOTING TRUST AGREEMENT RELATING TO SHARES OF INSYS THERAPEUTICS, INC. Dated as of: February 27, 2018Voting Trust Agreement • March 1st, 2018 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Delaware
VOTING TRUST AGREEMENT (this “Agreement”) dated as of February 27, 2018, is entered into among (i) the Persons set forth on Schedule A annexed hereto, as the initial Beneficiaries, (ii) Dr. John N. Kapoor (“Dr. Kapoor”), (iii) Insys Therapeutics, Inc., a Delaware corporation (the “Company”), and (iv) Bessemer Trust Company of Delaware, N.A., as the initial Trustee hereunder.
OFFICE LEASE By and Between CAZ 1 LLC, an Arizona limited liability company, as Landlord and Insys Therapeutics, Inc., a Delaware corporation as TenantOffice Lease • December 20th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations
SOFTGEL COMMERCIAL MANUFACTURING AND PACKAGING AGREEMENTManufacturing and Packaging Agreement • July 15th, 2011 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
This Softgel Commercial Manufacturing and Packaging Agreement (“Agreement”) is made this 21st day of March, 2011, by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”) and Insys Therapeutics, Inc., a Delaware corporation, having its principal place of business at 10220 S. 51st Street, Suite 2, Phoenix, AZ 85044 (“Client”).
LOAN AGREEMENTLoan Agreement • February 27th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Delaware
STANDARD FORM INDUSTRIAL BUILDING LEASE (MULTI-TENANT)Insys Therapeutics, Inc. • March 30th, 2011
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • February 27th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations
This Supply and Distribution Agreement is entered on this 20th day of May, 2011 (the “Effective Date”) between Mylan Pharmaceuticals Inc., a West Virginia corporation having its corporate offices at 781 Chestnut Ridge, Morgantown, West Virginia 26505, USA (“Mylan”); and Insys Therapeutics, Inc., a Delaware corporation having its corporate offices at 10220 South 51st Street, Suite 2, Phoenix, AZ 85044 (“Insys”).
Amendment No. 5 to Manufacturing AgreementManufacturing Agreement • May 10th, 2018 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Delaware
AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • February 27th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations
This Amendment to Supply and Distribution Agreement (“Amendment”) dated the 13th day of March, 2012, but effective as of May 20, 2011, by and between Mylan Pharmaceuticals Inc., a West Virginia corporation located at 781 Chestnut Ridge Road, Morgantown, West Virginia 26505, USA (“Mylan”) and Insys Therapeutics, Inc., a Delaware corporation located at 10220 South 51st Street, Suite 2, Phoenix, AZ 85044 (“Insys”).
INSYS THERAPEUTICS, INC. (“COMPANY”) EMPLOYMENT OFFER STATEMENT AND AGREEMENT (“OFFER STATEMENT”)Separation Agreement and General Release • November 5th, 2015 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Arizona
POSITION: Your title will be Executive Vice President and Chief Operating Officer (“COO”). During your employment, and excluding any periods of vacation and sick leave to which you are entitled, you agree to devote appropriate attention and time to the business and affairs of the Company and, to the extent necessary to discharge the responsibilities assigned to you in your position, to use your best efforts to perform faithfully and efficiently such responsibilities, which include observing (and to use reasonable efforts to communicate, monitor and discipline those employees under your supervision to observe), the policies of the Company and applicable legal and regulatory requirements. This COO position will evolve as you integrate into the company but at all times the Sales and Marketing functions will report to this COO position. In addition, at the time of your hire the following positions will also report to the COO: VP, Corporate Development & Strategy, VP, Business Intelligence
Credit AgreementCredit Agreement • October 23rd, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Arizona
This agreement dated as of October 17, 2013 is between JPMorgan Chase Bank, N.A. (together with its successors and assigns, the "Bank"), whose address is 201 N. Central Ave, 21st Floor, AZ1-1178, Phoenix, AZ 85004, and Insys Therapeutics, Inc. and Insys Pharma, Inc. (individually, the "Borrower" and if more than one, collectively, the "Borrowers"), whose address is 444 South Ellis Street, Chandler, AZ 85224.
SECOND AMENDMENT TO TRANSITION SERVICES AGREEMENTTransition Services Agreement • February 5th, 2020 • Insys Therapeutics, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO TRANSITION SERVICES AGREEMENT (this “Amendment”), dated as of January 30, 2020, is entered into by and between Benuvia Therapeutics Inc. (formerly known as Chilion Group Holdings US, Inc.), a Delaware corporation (“Buyer”), and Insys Therapeutics, Inc., a Delaware corporation (“Seller”). Buyer and Seller are each referred to individually as a “Party” and together as the “Parties”.
FIRST AMENDMENT TO SOFTGEL COMMERCIAL MANUFACTURING AND PACKAGING AGREEMENTManufacturing and Packaging Agreement • February 27th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Softgel Commercial Manufacturing and Packaging Agreement (this “Amendment”), is made as of this 5th day of March 2012 (“Effective Date”), by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”) and Insys Therapeutics, Inc., a Delaware corporation, having its principal place of business at 10220 S. 51st Street, Suite 2, Phoenix, AZ 85044 (“Client”).
Separation and Consulting AgreementSeparation and Consulting Agreement • April 1st, 2014 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Arizona
This Separation and Consulting Agreement ("Agreement") is entered into as of March 28, 2014 (the "Execution Date") by and between Insys Therapeutics, Inc., a Delaware corporation, (the "Insys") on behalf of itself, its subsidiaries and other corporate affiliates and each of their respective employees, officers, directors, owners, shareholders and agents (collectively referred to herein as, the "Insys Group"), and Dr. Larry Dillaha (the "Dr. Dillaha") (Insys and Dr. Dillaha are collectively referred to herein as the "Parties").
AMENDMENT NO. 1 TO LOAN AGREEMENTLoan Agreement • February 27th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) dated as of February 11, 2013, is between Bank of America, N.A. (the “Bank”) and Insys Therapeutics, Inc. (the “Borrower”).
RIGHTS AGREEMENTRights Agreement • August 18th, 2014 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Delaware
AMENDMENT NO. 2 TO LOAN AGREEMENT AND WAIVERLoan Agreement and Waiver • April 16th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 2 and Waiver (the “Amendment”) dated as of March 27, 2013, is between Bank of America, N.A. (the “Bank”) and Insys Therapeutics, Inc. (the “Borrower”).
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENTTransition Services Agreement • October 25th, 2019 • Insys Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this Amendment), dated as of October 23, 2019, is entered into by and between Chilion Group Holdings US, Inc., a Delaware corporation (“Buyer”)1, and Insys Therapeutics, Inc., a Delaware corporation (“Seller”). Buyer and Seller are each referred to individually as a “Party” and together as the “Parties”.
AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENTExclusive Licensing Agreement • February 29th, 2016 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENT (the “Agreement”), effective as of October 30, 2015 (the “Effective Date”), is made and entered into by and between Insys Therapeutics, Inc., a Delaware corporation having its principal place of business at 1333 S. Spectrum Blvd., Suite 100, Chandler, AZ 85286 (hereinafter called “PURCHASER”) and Aptargroup, Inc., a Delaware corporation having its principal place of business at 475 West Terra Cotta, Suite E, Crystal Lake, IL, 60014-9695 (hereinafter called “SELLER”). PURCHASER and SELLER being hereinafter called individually the “Party” and collectively the “Parties”.
LEASE AGREEMENTLease Agreement • September 3rd, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Texas
THIS LEASE AGREEMENT (this “Lease”) is entered into effective this 29th day of August, 2013 (the “Effective Date”), by and between Fog Break, Ltd., a Texas limited partnership (“Landlord”), and Insys Therapeutics, Inc., a Delaware corporation (“Tenant”).
AGREEMENT AND PLAN OF MERGER Among Insys Therapeutics, Inc. NeoPharm, Inc. and ITNI Merger Sub Inc. Dated as of October 29, 2010Agreement and Plan of Merger • March 30th, 2011 • Insys Therapeutics, Inc. • Delaware
AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 29, 2010 among Insys Therapeutics, Inc., a Delaware corporation (“Insys”), NeoPharm, Inc., a Delaware corporation (“NeoPharm”), and ITNI Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of NeoPharm (“Merger Sub”).
ASSET PURCHASE AGREEMENT BETWEEN RENAISSANCE LAKEWOOD, LLC AND INSYS THERAPEUTICS, INC. DATED AS OF DECEMBER 2, 2019Asset Purchase Agreement • December 3rd, 2019 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
FIRST AMENDMENT TO LEASETo Lease • February 27th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Arizona
This Amendment dated as of November 7, 2012, is entered into by and between Frye Road Two LLC (“Lessor”), an Arizona limited liability, company and INSYS Pharma dba INSYS Therapeutics Inc. (“Lessee”), a Delaware corporation.
Separation AgreementSeparation Agreement • November 5th, 2015 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Arizona
This Separation Agreement ("Agreement") is entered into as of November 4, 2015 (the "Execution Date") by and between Insys Therapeutics, Inc., a Delaware corporation, ("Insys") on behalf of itself, its subsidiaries and other corporate affiliates and each of their respective employees, officers, directors, owners, shareholders and agents (collectively referred to herein as, the "Insys Group"), and Michael L. Babich ("Babich") (Insys and Babich are collectively referred to herein as the "Parties").
Separation and Consulting AgreementSeparation and Consulting Agreement • October 31st, 2014 • Insys Therapeutics, Inc. • Pharmaceutical preparations • Arizona
This Separation and Consulting Agreement ("Agreement") is entered into as of October 31, 2014 (the "Execution Date") by and between Insys Therapeutics, Inc., a Delaware corporation (the "Insys"), on behalf of itself, its subsidiaries and other corporate affiliates and each of their respective employees, officers, directors, owners, shareholders and agents (collectively referred to herein as, the "Insys Group"), and Christopher Homrich ("Mr. Homrich") (Insys and Homrich are collectively referred to herein as the "Parties").
SOFTGEL COMMERCIAL MANUFACTURING AND PACKAGING AGREEMENTManufacturing and Packaging Agreement • May 9th, 2011 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
This Softgel Commercial Manufacturing and Packaging Agreement (“Agreement”) is made this 21st day of March, 2011, by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”) and Insys Therapeutics, Inc., a Delaware corporation, having its principal place of business at 10220 S. 51st Street, Suite 2, Phoenix, AZ 85044 (“Client”).
TRANSITION SERVICES AGREEMENTTransition Services Agreement • November 4th, 2019 • Insys Therapeutics, Inc. • Pharmaceutical preparations
This Transition Services Agreement (this “Agreement”) is made and entered into effective as of October 31, 2019 (the “Closing Date”), by and between Insys Therapeutics, Inc., a Delaware corporation (“Seller”), and Chilion Group Holdings US, Inc., a Delaware corporation (“Buyer”). Seller and Buyer may each be referred to herein as a “Party” and collectively as the “Parties.” Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Asset Purchase Agreement (as defined below).
AMENDMENT NUMBER ONE TO THE AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENTExclusive Licensing Agreement • August 7th, 2017 • Insys Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NUMBER ONE (“Amendment Number 1”) to the AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENT with an effective date of October 30, 2015 (the “A&R Agreement”), is hereby entered into as of April 6, 2017 with an effective date of January 1, 2017 (“Effective Date”), by and between INSYS MANUFACTURING, LLC, a Texas limited liability company, having its place of business at 1333 S. Spectrum Blvd., Suite 100, Chandler, AZ 85286 (“PURCHASER”) and APTARGROUP, INC., a Delaware corporation, having its place of business at 475 West Terra Cotta Avenue, Suite E, Crystal Lake, IL 60014-9695 (“SELLER”).
CHANDLER 101 BUSINESS CENTER OFFICE LEASEInsys Therapeutics, Inc. • February 27th, 2013 • Pharmaceutical preparations
